Insurmountable antagonism of AT-1015, a 5-HT2 antagonist, on serotonin-induced endothelium-dependent relaxation in porcine coronary artery

Differential inhibition by oxygen radicals of vasoactive amines-induced contractions in the porcine coronary artery

Reactive oxygen species (ROS) play an important role in normal metabolic and signaling processes. Excess ROS, however, can cause severe cardiovascular damage. Thus, the present study was designed to examine effects of H(2)O(2) and xanthine plus xanthin oxidase (X/XO) on the serotonin (5HT), histamine (His) and acetylcholine (ACh)-induced contractions of porcine coronary arteries. In addition, to explore the site of ROS formation and species of it, the inhibitory effects of edaravone and EDTA were also tested. 5HT- and His-induced contractions were suppressed by H(2)O(2) and X/XO treatment. However, these suppressions of ACh-induced contraction by H(2)O(2) treatment was relatively weak and X/XO treatment caused no suppression on ACh-induced contraction. In the presence of edaravone which is thought to be a scavenger for .OH, significant decrease of inhibition of 5HT- and His-induced contractions was observed when coronary artery strips were treated with X/XO, but not H(2)O(2). On the other hand, inhibitory effects by EDTA treatments were also observed in X/XO treatments. These results suggest that 1) ROSs produced by additions of H(2)O(2) or X/XO are considered to be responsible for several physiological functions of coronary artery contractions, 2) the site of ROS produced by X/XO system, probably .OH, was outside the cell, but the inhibitory action of H(2)O(2), was inside the cell, and 3) a low susceptibility of ACh-induced contraction to H(2)O(2) and X/XO may indicates the signal transduction pathway(s) of ACh-induced contraction is different from those of 5HT and His.

On the Mechanism of Interaction of Potent Surmountable and Insurmountable Antagonists with the Prostaglandin D2 Receptor CRTH2

Chemoattractant receptor-homologous molecule expressed on T helper 2 cells (CRTH2) has attracted interest as a potential therapeutic target in inflammatory diseases. Ramatroban, a thromboxane A2 receptor antagonist with clinical efficacy in allergic rhinitis, was recently found to also display potent CRTH2 antagonistic activity. Here, we present the pharmacological profile of three ramatroban analogs that differ chemically from ramatroban by either a single additional methyl group (TM30642), or an acetic acid instead of a propionic acid side chain (TM30643), or both modifications (TM30089). All three compounds bound to human CRTH2 stably expressed in human embryonic kidney 293 cells with nanomolar affinity. [3H]Prostaglandin D2 (PGD2) saturation analysis reveals that ramatroban and TM30642 decrease PGD2 affinity, whereas TM30643 and TM30089 exclusively depress ligand binding capacity (Bmax). Each of the three compounds acted as potent CRTH2 antagonists, yet the nature of their antagonism differed markedly. In functional assays measuring inhibition of PGD2-mediated 1) guanosine 5'-O-(3-thio)triphosphate binding, 2) beta-arrestin translocation, and 3) shape change of human eosinophils endogenously expressing CRTH2, ramatroban, and TM30642 produced surmountable antagonism and parallel rightward shifts of the PGD2 concentration-response curves. For TM30643 and TM30089, this shift was accompanied by a progressive reduction of maximal response. Binding analyses indicated that the functional insurmountability of TM30643 and TM30089 was probably related to long-lasting CRTH2 inhibition mediated via the orthosteric site of the receptor. A mechanistic understanding of insurmountability of CRTH2 antagonists could be fundamental for development of this novel class of anti-inflammatory drugs.